Market capitalization | $11.29b |
Enterprise Value | $21.28b |
P/E (TTM) P/E ratio | 9.94 |
EV/FCF (TTM) EV/FCF | 7.54 |
EV/Sales (TTM) EV/Sales | 9.39 |
P/S ratio (TTM) P/S ratio | 4.98 |
P/B ratio (TTM) P/B ratio | 1.65 |
Dividend yield | 3.31% |
Last dividend (FY24) | $0.84 |
As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.
11 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:
11 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,266 2,266 |
3%
3%
|
|
Gross Profit | - - |
-
|
|
EBITDA | 1,544 1,544 |
53%
53%
|
EBIT (Operating Income) EBIT | 1,544 1,544 |
53%
53%
|
Net Profit | 1,146 1,146 |
521%
521%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Head office | United Kingdom |
CEO | Pablo Legorreta |
Employees | 89 |
Founded | 1996 |
Website | royaltypharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.